Cue Biopharma (CUE) - Net Assets
Based on the latest financial reports, Cue Biopharma (CUE) has net assets worth $13.25 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($31.64 Million) and total liabilities ($18.40 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check CUE asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $13.25 Million |
| % of Total Assets | 41.86% |
| Annual Growth Rate | 10.82% |
| 5-Year Change | -77.82% |
| 10-Year Change | N/A |
| Growth Volatility | 108.01 |
Cue Biopharma - Net Assets Trend (2015–2024)
This chart illustrates how Cue Biopharma's net assets have evolved over time, based on quarterly financial data. Also explore CUE asset base for the complete picture of this company's asset base.
Annual Net Assets for Cue Biopharma (2015–2024)
The table below shows the annual net assets of Cue Biopharma from 2015 to 2024. For live valuation and market cap data, see how much is Cue Biopharma worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $17.50 Million | -52.81% |
| 2023-12-31 | $37.09 Million | -43.54% |
| 2022-12-31 | $65.68 Million | +0.29% |
| 2021-12-31 | $65.49 Million | -17.01% |
| 2020-12-31 | $78.91 Million | +44.57% |
| 2019-12-31 | $54.58 Million | +60.68% |
| 2018-12-31 | $33.97 Million | -44.86% |
| 2017-12-31 | $61.61 Million | +305.99% |
| 2016-12-31 | $15.17 Million | +118.71% |
| 2015-12-31 | $6.94 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cue Biopharma's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 33993527000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $62.00K | 0.35% |
| Other Components | $359.30 Million | 2053.27% |
| Total Equity | $17.50 Million | 100.00% |
Cue Biopharma Competitors by Market Cap
The table below lists competitors of Cue Biopharma ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hotel Royal Chihpen
TWO:5704
|
$26.57 Million |
|
White Horse Bhd
KLSE:5009
|
$26.58 Million |
|
Barinthus Biotherapeutics plc
NASDAQ:BRNS
|
$26.58 Million |
|
Vikas EcoTech Limited
NSE:VIKASECO
|
$26.59 Million |
|
Ohmyhome Limited Ordinary Shares
NASDAQ:OMH
|
$26.56 Million |
|
Lixte Biotechnology Holdings Inc
NASDAQ:LIXT
|
$26.54 Million |
|
KPS Consortium Bhd
KLSE:9121
|
$26.54 Million |
|
Tulikivi Oyj A
HE:TULAV
|
$26.53 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cue Biopharma's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 37,085,000 to 17,499,000, a change of -19,586,000 (-52.8%).
- Net loss of 40,674,000 reduced equity.
- New share issuances of 14,224,000 increased equity.
- Other factors increased equity by 6,864,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-40.67 Million | -232.44% |
| Share Issuances | $14.22 Million | +81.28% |
| Other Changes | $6.86 Million | +39.23% |
| Total Change | $- | -52.81% |
Book Value vs Market Value Analysis
This analysis compares Cue Biopharma's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 97.92x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 32.24x to 97.92x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $0.94 | $30.42 | x |
| 2016-12-31 | $0.74 | $30.42 | x |
| 2017-12-31 | $2.98 | $30.42 | x |
| 2018-12-31 | $1.69 | $30.42 | x |
| 2019-12-31 | $2.48 | $30.42 | x |
| 2020-12-31 | $2.75 | $30.42 | x |
| 2021-12-31 | $2.09 | $30.42 | x |
| 2022-12-31 | $1.84 | $30.42 | x |
| 2023-12-31 | $0.81 | $30.42 | x |
| 2024-12-31 | $0.31 | $30.42 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cue Biopharma utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -232.44%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -437.97%
- • Asset Turnover: 0.29x
- • Equity Multiplier: 1.84x
- Recent ROE (-232.44%) is below the historical average (-87.21%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -27.80% | 0.00% | 0.00x | 1.05x | $-2.62 Million |
| 2016 | -50.47% | 0.00% | 0.00x | 1.07x | $-9.18 Million |
| 2017 | -37.71% | 0.00% | 0.00x | 1.09x | $-29.39 Million |
| 2018 | -114.74% | -3411.53% | 0.03x | 1.34x | $-42.38 Million |
| 2019 | -67.23% | -1061.25% | 0.05x | 1.31x | $-42.16 Million |
| 2020 | -56.75% | -1419.79% | 0.03x | 1.26x | $-52.68 Million |
| 2021 | -67.43% | -295.56% | 0.18x | 1.27x | $-50.71 Million |
| 2022 | -80.71% | -4257.83% | 0.01x | 1.39x | $-59.58 Million |
| 2023 | -136.80% | -924.10% | 0.09x | 1.66x | $-54.44 Million |
| 2024 | -232.44% | -437.97% | 0.29x | 1.84x | $-42.42 Million |
Industry Comparison
This section compares Cue Biopharma's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cue Biopharma (CUE) | $13.25 Million | -27.80% | 1.39x | $26.56 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Cue Biopharma
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a novel approach to induce and expand antigen specific Tregs for regulating disease causing autoreactive Teff cells which is in preclinical tria… Read more